Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Patent foramen ovale and atrial septal defect closure: mostly patients under 65. Main billing specialty: interventional cardiology.
Medicare fee-for-service PFO & septal closure cases in the 6 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 96% on average (6 state-years, 2020–2024): small markets swing, so treat it as rough.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 5 | 312+5.6%/yr | +5.6%/yr | 0.11.0× | 0% | 200 in 2030−7.3%/yr |
| Florida | 0 | 224+0.5%/yr | +0.5%/yr | 0.11.1× | 0% | 310 in 2030+5.8%/yr |
| Texas | 1 | 171−2.9%/yr | −2.9%/yr | 0.10.8× | 0% | 210 in 2030+3.5%/yr |
| New York | 2 | 153+0.3%/yr | +0.3%/yr | 0.10.9× | 0% | 150 in 2030+0.1%/yr |
| Arizona | 2 | 121+7.6%/yr | +7.6%/yr | 0.21.7× | 0% | 170 in 2030+5.8%/yr |
| Illinois | 0 | 116+4.3%/yr | +4.3%/yr | 0.10.9× | 0% | 80 in 2030−5.6%/yr |
Professional codes (what the surgeon bills): CPT 93580.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 133 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 2 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Abbott | 74 |
| W L Gore & Associates | 59 |
Product codes: MLV (transcatheter septal occluder). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 100% of the cases CMS names in California; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Coronary intervention (PCI) | 5,056 | 218,309−6.5%/yr | −6.5%/yr | 236,300 in 2030+1.3%/yr |
| Structural heart (TAVR, TEER) | 2,849 | 63,491+3.8%/yr | +3.8%/yr | 90,800 in 2030+6.2%/yr |
| Mechanical circulatory support | 56 | 17,228−4.4%/yr | −4.4%/yr | 19,300 in 2030+1.9%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 2 companies reported engagement with surgeons in the covered states worth $614K in consulting, speaking, meals and travel tied to these products, about $61K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.